Hemato Oncology Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Hemato Oncology Testing Market Report Segments the Industry Into by Product & Services (Assay Kits and Reagents, Services), by Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Others), by Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technology), by End User (Hospitals, Academic & Research Institutes, Other End-Users), and Geography.

Global Hemato Oncology Testing Market Size and Share

Global Hemato Oncology Testing Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Global Hemato Oncology Testing Market with other markets in Healthcare Industry

Global Hemato Oncology Testing Market Analysis by Mordor Intelligence

The hemato oncology testing market size stands at USD 4.37 billion in 2025 and is forecast to reach USD 7.87 billion by 2030, reflecting a 12.5% CAGR that places the hemato oncology testing market among the faster-growing segments of clinical diagnostics. The expansion is powered by widespread adoption of artificial intelligence in diagnostic workflows, routine use of liquid biopsy, and the steady shift from first-generation genetic assays to standardised next-generation sequencing platforms. The FDA’s May 2025 decision to reclassify DNA-based minimal residual-disease (MRD) tests for hematological malignancies into Class II status reduces regulatory friction and accelerates commercial roll-out fda.gov. Heightened demand for comprehensive molecular profiling, coupled with growing physician confidence in non-invasive sampling, reinforces test utilisation across both community hospitals and specialist laboratories. In parallel, automation in cytogenetics, digital pathology, and cloud-based bioinformatics is improving laboratory throughput and lowering per-sample costs, sustaining double-digit revenue growth. 

Key Report Takeaways

  • By product & services, services led with 68.40% of the hemato oncology testing market share in 2024, whereas assay kits and reagents are projected to advance at a 13.05% CAGR through 2030.
  • By cancer type, lymphoma testing commanded 40.72% of the hemato oncology testing market size in 2024, while leukemia testing is forecast to register the fastest 13.76% CAGR to 2030.
  • By technology, PCR retained 43.15% of the hemato oncology testing market share in 2024; immunohistochemistry is expected to expand at a 14.11% CAGR during the outlook period.
  • By end user, hospitals accounted for a dominant 57.48% share of the hemato oncology testing market size in 2024, yet reference and specialty laboratories are set for 13.81% CAGR growth.
  • By geography, North America captured 42.15% revenue share in 2024, whereas Asia-Pacific is positioned to grow at 14.28% CAGR to 2030. 

Segment Analysis

By Product & Services: Services Drive Market Leadership

Services contributed 68.40% revenue in 2024, making them the single largest slice of the hemato oncology testing market. Hospital networks, community clinics, and pharma sponsors rely on specialised service providers for end-to-end workflows that span sample logistics, nucleic-acid extraction, sequencing, bioinformatics, and variant curation. The segment’s high share reflects the capital intensity of molecular laboratories and the scarcity of in-house expertise. In value terms, this leadership translates into USD 2.11 billion of the 2025 hemato oncology testing market size. Market outlook remains strong as laboratories outsource overflow volumes to combat staff shortages and reduce turnaround-time penalties. 

Assay kits and reagents, although smaller, exhibit a 13.05% CAGR through 2030, the fastest within the product grid. Growth centres on multiplex PCR panels, single-tube library prep chemistries, and lyophilised reagents that support field deployment. Firms such as QIAGEN announced sample-to-result platforms that integrate extraction and assay setup, enhancing consistency and lowering operator error. These improvements encourage smaller laboratories to launch molecular menus, adding incremental volume to the hemato oncology testing market. 

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Cancer Type: Lymphoma Leadership Amid Leukemia Acceleration

Lymphoma testing held 40.72% of the hemato oncology testing market share in 2024, reflecting the diverse spectrum of Hodgkin and non-Hodgkin entities that each demand immunophenotyping, gene rearrangement studies, and mutational panels. The downstream linkage to antibody-drug conjugates and CAR-T therapies further entrenches comprehensive testing as a clinical imperative. Consequently, lymphoma accounted for USD 1.78 billion of the 2025 hemato oncology testing market size. 

Leukemia testing, while smaller, grows at 13.76% CAGR as MRD surveillance becomes standard of care. FDA-cleared assays such as clonoSEQ enable quantitative tracking of residual clones, guiding therapy adjustment and transplant planning. Liquid biopsy approaches that monitor nucleosomal DNA fragmentation promise earlier relapse detection. As payers recognise the prognostic value of serial monitoring, volume growth in leukemia tests will meaningfully lift overall revenue for the hemato oncology testing market.

By Technology: PCR Dominance Challenged by IHC Innovation

PCR contributed 43.15% of 2024 revenue, underlining its status as a laboratory workhorse for fusion gene detection, copy-number analysis, and pathogen screening. The entrenched install base, low cost per reaction, and regulatory familiarity reinforce ongoing demand. Against this backdrop, PCR captured USD 1.89 billion within the 2025 hemato oncology testing market size. 

Immunohistochemistry (IHC) is poised for a 14.11% CAGR through 2030 as multiplexed antibody panels and automated stainers elevate diagnostic throughput. Recent advances allow simultaneous visualisation of up to nine markers on a single slide, delivering richer phenotypic context for haematopathologists. AI-based image analytics extract quantitative parameters, rescuing information that manual reads can miss, and thereby justify premium reimbursement. The resulting productivity gains and clinical value position IHC as a credible challenger to PCR within the hemato oncology testing market.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospital Dominance Amid Laboratory Specialisation

Hospitals generated 57.48% of 2024 billings, a testament to their gatekeeper role in oncology care. Integrated test-and-treat models allow oncologists to order molecular panels and act on results within the same facility, reinforcing hospital stickiness. Hospital expenditure reached USD 2.42 billion in the 2025 hemato oncology testing market size. 

Reference and specialty laboratories, however, advance at a 13.81% CAGR by offering deep assay menus and robust logistics. Partnerships such as Labcorp–Ascension illustrate mutually beneficial outsourcing, where health-system staff shortages are offset by external capacity while Labcorp gains sample inflow. Similar tie-ups in Africa, supported by grants from diagnostic vendors, demonstrate how external expertise can expand access to complex tests. These collaborative models should steadily lift the volume processed by independent labs, expanding the hemato oncology testing market.

Geography Analysis

North America led with 42.15% revenue share in 2024 as mature reimbursement structures and early technology adoption sustained high test utilisation. Despite rising Medicare denials, the United States continues to approve new assays rapidly, including Class II MRD devices that shorten time-to-market. Laboratory consolidation, exemplified by BioReference Health asset acquisitions, yields economies of scale that protect margins. Canada’s provincial health systems are introducing centralised genomic programmes, and Mexico’s private sector is scaling liquid biopsy services for medical tourism. Together, these dynamics support mid-single-digit growth in an otherwise saturated segment of the hemato oncology testing market. 

Asia-Pacific is the most dynamic region, posting a 14.28% CAGR forecast to 2030. Government initiatives in China, Japan, and India fund laboratory modernisation and subsidise molecular panels as standard care. Sysmex recorded a 119.2% increase in regional hematology revenue during the first quarter of fiscal 2025, underscoring export demand for advanced analysers. Regulatory frameworks are converging toward IVD harmonisation, trimming approval times and stimulating local production. Southeast Asian countries employing decentralised point-of-care PCR platforms are leapfrogging legacy infrastructure, registering new test volumes that lift the hemato oncology testing market across the region. 

Europe maintains balanced growth as public payers weigh cost-effectiveness carefully. Pan-EU initiatives encourage data interoperability, facilitating cross-border clinical trials and reference-lab collaborations. Germany and France are enlarging reimbursement codes for NGS panels, and the United Kingdom’s Genomic Medicine Service continues to add haematology indications. Eastern European health ministries fund tele-pathology pilots that connect local hospitals with central expertise, modestly raising per-capita test rates. Meanwhile, the Gulf Cooperation Council states invest in high-end oncology centres that import US- and EU-cleared assays, and South Africa positions itself as a sub-Saharan reference hub. Collectively, these trends sustain broad geographical diversity and underpin the global expansion of the hemato oncology testing market.

Hemato Oncology Testing Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The hemato oncology testing market is moderately fragmented, with the top five companies controlling an estimated 48% of 2024 revenue. Large integrated players combine reagent portfolios, sequencing platforms, and accredited service labs to deliver turnkey solutions that ease adoption barriers. Smaller innovators compete by focusing on liquid biopsy, AI-enabled informatics, or microfluidic sample prep. Competitive intensity has sharpened because technical advances reach the market faster following FDA’s Class II reclassification and evolving EU IVDR pathways. 

Strategic alliances remain a principal growth lever. Adaptive Biotechnologies and NeoGenomics signed an exclusive MRD monitoring pact, pooling a proprietary T-cell receptor assay with a national laboratory network to widen test access. Agilent partnered with Incyte to develop companion diagnostics aligning with pipeline drugs, expanding Agilent’s IVD footprint. Servier and QIAGEN plan a PCR-based IDH1 companion test that promises rapid turnaround for AML care. Acquisitions also shape supply: Labcorp absorbed Incyte Diagnostics’ clinical testing business to deepen oncology competence, while several regional labs merged to achieve reimbursement clout. 

Technology differentiation is increasingly data-centric. Vendors tout encrypted cloud repositories that comply with the NIST genomic data cybersecurity framework, an attribute that resonates with hospital privacy officers. AI algorithms embedded within digital pathology viewers help new entrants punch above their weight by automating routine classification tasks. Meanwhile, incumbents leverage scale to bundle instrumentation, reagents, and analytics into subscription models that lock-in customers. Price competition is muted as buyers value turnaround time and clinical sensitivity over unit cost, allowing vendors to preserve healthy margins and reinvest in R&D that sustains innovation within the hemato oncology testing market.

Global Hemato Oncology Testing Industry Leaders

  1. Abbott

  2. QIAGEN

  3. F. Hoffmann-La Roche Ltd

  4. Illumina Inc.

  5. Thermo Fisher Scientific Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Picture4.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2024: Agilent Technologies entered an agreement with Incyte to co-develop companion diagnostics across the latter’s hematology and oncology portfolio.
  • December 2023: Huntsman Cancer Institute reported that NGS reliably predicts relapse risk in paediatric malignancies, supporting broader adoption in children’s oncology programmes.
  • March 2023: Servier and QIAGEN began a strategic partnership to create a PCR-based companion diagnostic for IDH1-mutated AML, aiming for rapid lab turnaround and global distribution.

Table of Contents for Global Hemato Oncology Testing Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing incidence of hematologic cancers
    • 4.2.2 Growing demand for personalized therapy
    • 4.2.3 Advancements in molecular diagnostic technologies
    • 4.2.4 Rising adoption of non-invasive liquid biopsy
    • 4.2.5 AI-driven decision support in heme-oncology labs
    • 4.2.6 Decentralized PoC molecular platforms in emerging markets
  • 4.3 Market Restraints
    • 4.3.1 Unfavorable reimbursement scenario
    • 4.3.2 High cost of next-generation sequencing tests
    • 4.3.3 Shortage of skilled molecular pathologists
    • 4.3.4 Genomic-data interoperability & cybersecurity gaps
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product & Services
    • 5.1.1 Assay Kits & Reagents
    • 5.1.1.1 PCR assay kits
    • 5.1.1.2 NGS panels & library prep kits
    • 5.1.1.3 IHC/Flow-cytometry reagents
    • 5.1.2 Services
  • 5.2 By Cancer Type
    • 5.2.1 Leukemia
    • 5.2.2 Lymphoma
    • 5.2.3 Multiple Myeloma
    • 5.2.4 Other Hematologic Malignancies
  • 5.3 By Technology
    • 5.3.1 Polymerase Chain Reaction (PCR)
    • 5.3.2 Next-Generation Sequencing (NGS)
    • 5.3.3 Immunohistochemistry (IHC)
    • 5.3.4 Flow Cytometry
    • 5.3.5 Other Technologies
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Reference & Specialty Laboratories
    • 5.4.3 Other End-Users
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 F. Hoffmann-La Roche Ltd
    • 6.3.2 Abbott Laboratories
    • 6.3.3 Thermo Fisher Scientific Inc.
    • 6.3.4 QIAGEN
    • 6.3.5 Illumina Inc.
    • 6.3.6 Bio-Rad Laboratories Inc.
    • 6.3.7 Guardant Health
    • 6.3.8 Adaptive Biotechnologies
    • 6.3.9 Invitae Corp. / ArcherDX
    • 6.3.10 Cepheid (Danaher)
    • 6.3.11 EntroGen Inc.
    • 6.3.12 NeoGenomics Inc.
    • 6.3.13 Sysmex Corp.
    • 6.3.14 Beckman Coulter (Danaher)
    • 6.3.15 Siemens Healthineers
    • 6.3.16 Becton, Dickinson and Company
    • 6.3.17 Labcorp Oncology
    • 6.3.18 Precipio Inc.
    • 6.3.19 Biotype GmbH
    • 6.3.20 Invivoscribe Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Hemato Oncology Testing Market Report Scope

As per the scope of the report, hemato-oncology refers to the science which is associated with the diagnosis, treatment, and prevention of blood-related diseases and cancer. The Hemato Oncology Testing Market is segmented by Product & Services (Assay Kits and Reagents, Services), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, and Others), Technology (Polymerase chain reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Other Technology), End-User (Hospitals, Academic & Research Institutes, and Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product & Services Assay Kits & Reagents PCR assay kits
NGS panels & library prep kits
IHC/Flow-cytometry reagents
Services
By Cancer Type Leukemia
Lymphoma
Multiple Myeloma
Other Hematologic Malignancies
By Technology Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
Flow Cytometry
Other Technologies
By End User Hospitals
Reference & Specialty Laboratories
Other End-Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product & Services
Assay Kits & Reagents PCR assay kits
NGS panels & library prep kits
IHC/Flow-cytometry reagents
Services
By Cancer Type
Leukemia
Lymphoma
Multiple Myeloma
Other Hematologic Malignancies
By Technology
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
Flow Cytometry
Other Technologies
By End User
Hospitals
Reference & Specialty Laboratories
Other End-Users
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current Global Hemato Oncology Testing Market size?

The hemato oncology testing market size is USD 4.37 billion in 2025, rising to USD 7.87 billion by 2030 on a 12.5% CAGR trajectory.

Who are the key players in Global Hemato Oncology Testing Market?

Abbott, QIAGEN, F. Hoffmann-La Roche Ltd, Illumina Inc. and Thermo Fisher Scientific Inc. are the major companies operating in the Global Hemato Oncology Testing Market.

Which is the fastest growing region in Global Hemato Oncology Testing Market?

A-Pacific is projected to expand at 14.28% CAGR through 2030, driven by infrastructure upgrades and supportive regulations.

Which region has the biggest share in Global Hemato Oncology Testing Market?

In 2025, the North America accounts for the largest market share in Global Hemato Oncology Testing Market.

Page last updated on: June 20, 2025

Global Hemato Oncology Testing Market Report Snapshots